Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 12, 2010, Pages 2655-2665

  Hong, Soon Jun ^a   Kim, Sung Tae ^b   Kim, Tae Jin ^b   Kim, Eun Ok ^b   Ahn, Chul Min ^a   Park, Jae Hyoung ^a   Kim, Je Sang ^a   Lee, Kyung Mi ^b   Lim, Do Sun ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

diabetes; inflammation; pioglitazone; restenosis; zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHEMOKINE RECEPTOR; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA DERIVATIVE; ZOTAROLIMUS;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELUTING STENT; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTRAVASCULAR ULTRASOUND; MALE; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INTERLEUKIN-6; KILLER CELLS, NATURAL; LIPIDS; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECEPTORS, CCR2; REPUBLIC OF KOREA; SINGLE-BLIND METHOD; SIROLIMUS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 78650416365     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.212670     Document Type: Article

References (41)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
2. Silva JA, Ramee SR, White CJ, Collins TJ, Jenkins JS, Nunez E, Zhang S, Jain SP. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J. 1999;138:446-455.
3. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109:476-480.
4. Lee MS, Jamel F, Kedia G, Chang G, Kapoor N, Forrester J, Czer L, Zimmer R, DeRobertis M, Trento A, Makkar RR. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. Int J Cardiol. 2007;123:34-42.
5. Wood TC, Marks AR. Drug-eluting stents. Annu Rev Med. 2004;55: 169-178.
6. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, Ro YM, Lim DS. Multiple predictors of coronary restenosis after drug- eluting stent implantation in diabetic patients. Heart. 2006;92:1119-1124.
7. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? Circulation. 2005;112:2759-2761.
8. Camejo G. Differential antiatherogenic effect of PPARa versus PPAR7 agonist. Arterioscler Thromb Vasc Biol. 2005;25:1763-1764.
9. Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, Saito M, Momomura SI, Kawakami M. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J. 2007;153:762.e1-762.e7.
10. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29:101-106.
11. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci. 2008;114:257-264.
12. Clementi F, Luozzo M, Mango R, Luciani G, Trivisonno A, Pizzuto F, Martuscelli E, Mehta JL, Romeo F. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. J Cardiovasc Med. 2009;10:231-237.
13. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB III, McCal-lister BD, Smith SC Jr, Ullyot DJ. Guidelines for percutaneous transluminal coronary angioplasty: a report of the Am Heart Association/Am College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1993;88:2987-3007.
14. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-1878.
15. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol. 2007;100:1625-1629.
16. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation. 2005;112:2792-2798.
17. Son SW, Kim EO, Ryu ES, Kim TJ, Kim JN, Choi JE, Kye YC, Lee KM. Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. Br J Dermatol. 2009;161:281-288.
18. Jung S, Park YK, Lee H, Shin JH, Lee GR, Park SH. TGF-beta-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses. Exp Mol Med. 2010;42:187-194.
19. Ahn HJ, Park J, Song JS, Ju MK, Kim MS, Ha H, Song KH, Kim YS. Mycophenolic acid inhibits oleic acid-induced vascular smooth muscle cell activation by inhibiting cellular reactive oxygen species. Transplantation. 2007;84:632-638.
20. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119: 79-84.
21. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem. 2002;277:37487-37491.
22. Kosmala W, Derzhko R, Przewlocka-Kosmala M, Orda A, Mazurek W. Plasma levels of TNF-a, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis. 2008; 19:375-382.
23. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA. 2005;102:8686-8691.
24. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol. 2001;12:175-180.
25. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010;55:1553-1565.
26. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev. 2008;24:14-26.
27. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPAR in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
28. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or sim-vastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49: 290-297.
29. Zhang WY, Schwartz EA, Permana PA, Reaven PD. Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol. 2008;28:2312-2318.
30. Whitman SC, Rateri DL, Szilvassy SJ, Yokoyama W, Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol. 2004;24:1049-1054.
31. brightCD16-NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol. 2006;36:118-128.
32. Bos JD, Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol. 2005;152:1098-1107.
33. Zhang X, Rodriguez-Galán MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM, Shimozato O, Reynolds DA, Young HA. Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells. Blood. 2004;104:3276-3284.
34. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Gladue R, Rollins B. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol. 1997;62:577-580.
35. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327-334.
36. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007;115:553-561.
37. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000;84: 83-87.
38. Ling HY, Hu B, Wang BX, Zu XY, Feng SD, Ou HS, Zhou SH, Liao DF. Effects of rosiglitazone on the proliferation of vascular smooth muscle cell induced by high glucose. Cardiovasc Drugs Ther. 2008;22:453-460.
39. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998; 83:1097-1103.
40. Sripalakit P, Maphanta S, Neamhom P, Saraphanchotiwitthaya A, Polnok S, Yokubol D. Comparative study on the bioequivalence of two formulations of pioglitazone tablet in healthy Thai male volunteers. Drug Dev Ind Pharm. 2007;33:1362-1368.
41. Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPAR-gamma in the cardiovascular system. PPAR Res. 2008;2008:745-804.